Assiri Khalil, Alqarni Abdullah, Almubarak Hussain, Mohammed Kaleem Sultan, Alassiri Saeed, Baig Fawaz Abdul Hamid, Muhammed Ajmal, Kota Mohammad Zahir, Dawasaz Ali Azhar, Alqahtani Ali Mosfer, Assiri Hassan Ahmed, Arem Saeed Abdullah, Abubaker Abbas Ali Salma, Luqman Mannakandath Master
Department of Diagnostic Sciences and Oral Biology, King Khalid University College of Dentistry, Abha, Saudi Arabia.
Department of Oral and Maxillofacial Surgery, King Khalid University College of Dentistry, Abha, Saudi Arabia.
Med Sci Monit. 2025 May 14;31:e946650. doi: 10.12659/MSM.946650.
BACKGROUND This research is aimed at minimizing the patient's discomfort and suffering from temporomandibular joint disorders through less-invasive procedures to evaluate the efficacy of proliferative injection therapy, particularly prolotherapy, in fearful patients with temporomandibular joint (TMJ) disorders. MATERIAL AND METHODS A structured questionnaire covering symptom intensity and presence or absence of TMJ clicking and joint hypermobility in patients with confirmed temporomandibular disorder symptoms was completed by patients. Mouth opening and maximum incisor height was measured in millimeters. Degree of pain was obtained from the Visual Analog Scale score. The patients were referred to an oral surgeon who did the prolotherapy procedure, and this was repeated at the end of 1, 3, and 6 months. The collected data were analyzed using the Chi-square and t-tests. RESULTS The patients' pain decreased from the third month of treatment until the end of the sixth month of the treatment program, and patient mouth opening ability was significantly different (F=3. 56; df=2; P<0. 05). After a duration of 3 months of the process of treatment, crepitus and periauricular discomfort were reduced. In terms of pain and mouth opening, prolotherapy in treating temporomandibular disorder was generally beneficial as shown by the P<0.05 scores. CONCLUSIONS From this evaluation, prolotherapy using 50% dextrose as a single injection via a conventional protocol, which can be single dosage or several doses, is recommended as treatment for chronic recurring dislocations and mandibular subluxations. Recurrent or severe cases can only be managed through operations. Much larger studies with greater sample sizes and even longer follow-up periods are necessary for the results of this study to be supported.
背景 本研究旨在通过侵入性较小的程序,将颞下颌关节紊乱患者的不适和痛苦降至最低,以评估增殖注射疗法,特别是注射疗法,对患有颞下颌关节(TMJ)紊乱的恐惧患者的疗效。
材料与方法 患者完成了一份结构化问卷,内容涵盖确诊为颞下颌紊乱症状患者的症状强度以及TMJ弹响和关节活动过度的有无。以毫米为单位测量开口度和最大切牙高度。疼痛程度通过视觉模拟量表评分获得。患者被转介给一位进行注射疗法的口腔外科医生,该治疗在1、3和6个月结束时重复进行。使用卡方检验和t检验对收集到的数据进行分析。
结果 患者的疼痛从治疗的第三个月到治疗方案的第六个月末有所减轻,患者的开口能力有显著差异(F = 3.56;自由度 = 2;P < 0.05)。在治疗过程持续3个月后,关节摩擦音和耳周不适减轻。就疼痛和开口度而言,注射疗法在治疗颞下颌紊乱方面总体上是有益的,P < 0.05的评分表明了这一点。
结论 从该评估来看,建议使用50%葡萄糖作为单一注射剂,通过传统方案进行注射疗法,该方案可以是单次剂量或多次剂量,用于治疗慢性复发性脱位和下颌半脱位。复发性或严重病例只能通过手术处理。需要进行更大规模、样本量更大且随访期更长的研究来支持本研究结果。